DOW JONES NEWSWIRES 
 

Drug maker Bristol-Myers Squibb Co. (BMY) said the U.S. Food and Drug Administration needs additional time to finish a review of the license application for the company's melanoma treatment, pushing back its decision date by three months.

The FDA said it now expects to make a decision on the license by March 26 of next year, rather than Dec. 25 of this year. Bristol has complied with a request for further analysis of data. Ipilimumab is an experimental treatment for advanced melanoma, a type of skin cancer.

In August, the FDA had agreed to give ipilimumab a priority review, focusing on the use of the drug on patients who have previously received treatment for melanoma.

Ipilimumab is also under review by other health agencies.

Last month, Bristol-Myers said its third-quarter profit declined slightly from a year earlier on flat sales. The drug maker's fortunes have brightened since a series of challenges in the mid-2000s, including legal problems and temporary generic competition for its top product, the anticlotting drug Plavix.

Shares closed at $26.90 and were inactive in recent late trading.

 
 

-By Nathan Becker, Dow Jones Newswires; 212-416-2855; nathan.becker@dowjones.com;

 
 
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Bristol Myers Squibb Charts.